Computationally Designed VLP Vaccines

By utilizing computationally designed proteins that self-assemble into virus-like particles (VLPs), we are able to readily manufacture VLPs displaying complex antigens to target significant unmet medical needs.

RSV Vaccine
Our first vaccine candidate, IVX-121, is being developed to protect older adults from respiratory syncytial virus (RSV) disease.
Icosavax is unlocking a whole class of challenging vaccine targets to improve human health.

Icosavax, Inc.

1616 Eastlake Avenue E. Suite 208 
Seattle, WA 98102

  • White Twitter Icon
  • White Facebook Icon
  • White LinkedIn Icon

© 2019 Icosavax, Inc. All rights reserved.